Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
A recently approved drug for treatment-resistant depression was branded as a wonder drug, but serious questions have been raised about its approval process, effectiveness and safety, the Center for Public Integrity reports.
Why it matters: "For veterans whose ranks are plagued by depression and suicides, much is at stake," CPI writes. "A drug that offers [a] fast and lasting answer for treatment-resistant depression would be a godsend. But is this drug the answer?"
What's new: A VA committee will decide this week whether to require that Spravato be available to VA pharmacies.
- If it is, that could be a huge plus for Johnson & Johnson's marketing of the drug.
Flashback: President Trump took a personal interest in the drug, Spravato, thinking it would be great for the Veterans Affairs system, and reportedly wanted the agency to buy "truckloads" of the drug.
Go deeper: FDA approves fast-acting antidepressant nasal spray, esketamine